Literature DB >> 16572427

Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.

Servi J C Stevens1, Sandra A W M Verkuijlen, Bambang Hariwiyanto, Dewi K Paramita, Jajah Fachiroh, Marlinda Adham, I Bing Tan, Sophia M Haryana, Jaap M Middeldorp.   

Abstract

Nasopharyngeal carcinoma (NPC) is the most prevalent ENT-tumour in Indonesia. We investigated the primary diagnostic value of Epstein-Barr virus (EBV) DNA load and mRNA detection in noninvasive nasopharyngeal (NP) brushings, obtained prospectively from consecutive Indonesian ENT-patients with suspected NPC (N=106) and controls. A subsequent routine NP biopsy was taken for pathological examination and EBER-RISH, yielding 85 confirmed NPC and 21 non-NPC tumour patients. EBV DNA and human DNA load were quantified by real-time PCR. NP brushings from NPC patients contained extremely high EBV DNA loads compared to the 88 non-NPC controls (p<0.0001). Using mean EBV DNA load in controls plus 3 SD as cut-off value, specificity, sensitivity, positive and negative predictive values were 98, 90, 97 and 91%, respectively. Epstein-Barr nuclear antigen 1 (EBNA1) and the carcinoma-specific BARF1 mRNA were detected by nucleic acid sequence based amplification and found in 86 and 74% of NP brushings, confirming NPC tumour cell presence. EBV RNA positivity was even higher in fresh samples stored at -80 degrees C until RNA expression analyses (88% for both EBNA1 and BARF1). EBV RNA-negative NP brushings from proven NPC cases had the lowest EBV DNA loads, indicating erroneous sampling. No EBV mRNA was detected in NP brushings from healthy donors and non-NPC patients. In conclusion, EBV DNA load measurement combined with detection of BARF1 mRNA in simple NP brushings allows noninvasive NPC diagnosis. It reflects carcinoma-specific EBV involvement at the anatomical site of tumour development and reduces the need for invasive biopsies. This procedure may be useful for confirmatory diagnosis in large serological NPC screening programs and has potential as prognostic tool. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572427     DOI: 10.1002/ijc.21914

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.

Authors:  E K Hoebe; C Wille; E S Hopmans; A R Robinson; J M Middeldorp; S C Kenney; A E Greijer
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

2.  Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.

Authors:  Anna E Coghill; Wan-Lun Hsu; Ruth M Pfeiffer; Hedy Juwana; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Jen-Yang Chen; Chien-Jen Chen; Jaap M Middeldorp; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-27       Impact factor: 4.254

3.  Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.

Authors:  Sharon D Stoker; Maarten A Wildeman; Zlata Novalic; Renske Fles; Vincent van der Noort; Remco de Bree; Weibel W Braunius; Guido B van den Broek; Bas Kreike; Kenneth W Kross; Hedy Juwana; Octavia Ramayanti; Sandra A W M Verkuijlen; Jan Paul de Boer; Astrid E Greijer; Jaap M Middeldorp; I Bing Tan
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-01       Impact factor: 2.503

4.  Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue.

Authors:  Alexander A Benders; Weihua Tang; Jaap M Middeldorp; Astrid E Greijer; Leigh B Thorne; William K Funkhouser; W Kimryn Rathmell; Margaret L Gulley
Journal:  Head Neck Pathol       Date:  2009-11-12

5.  Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.

Authors:  E K Hoebe; S H Hutajulu; J van Beek; S J Stevens; D K Paramita; A E Greijer; J M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

6.  Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Authors:  Sharon D Stoker; Zlata Novalić; Maarten A Wildeman; Alwin D R Huitema; Sandra A W M Verkuijlen; Hedy Juwana; Astrid E Greijer; I Bing Tan; Jaap M Middeldorp; Jan Paul de Boer
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-29       Impact factor: 4.553

7.  Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.

Authors:  E Muraro; E Vaccher; C Furlan; E Fratta; G Fanetti; D A Fae'; D Martorelli; M Cangemi; J Polesel; F Navarria; C Gobitti; E Comaro; C Scaini; C Pratesi; S Zanussi; V Lupato; G Grando; V Giacomarra; S Sulfaro; L Barzan; R Dolcetti; A Steffan; V Canzonieri; G Franchin
Journal:  Pathol Oncol Res       Date:  2020-06-21       Impact factor: 3.201

Review 8.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

9.  Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma.

Authors:  Susanna H Hutajulu; Eveline K Hoebe; Sandra Awm Verkuijlen; Jajah Fachiroh; Bambang Hariwijanto; Sofia M Haryana; Servi Jc Stevens; Astrid E Greijer; Jaap M Middeldorp
Journal:  Infect Agent Cancer       Date:  2010-09-19       Impact factor: 2.965

10.  Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma.

Authors:  Katherine Cosmopoulos; Michiel Pegtel; Jared Hawkins; Howell Moffett; Carl Novina; Jaap Middeldorp; David A Thorley-Lawson
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.